ArticleJournal of diabetes science and technology2023
Lipohypertrophy and Insulin: An Update From the Diabetes Technology Society.
Article in Journal of diabetes science and technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Article
- Article
- Insulin Delivery Hardware: Pumps and Pens.Diabetes technology & therapeutics · 2026Article
- Insulin-Induced Lipohypertrophy.JCEM case reports · 2025Article
- Barriers to the Prevention of Insulin Injection-Associated Lipohypertrophy for Individuals with Diabetes.Patient preference and adherence · 2025Article
- The Distinct Ultrasound Characteristics and Prognostic Features of Insulin-Induced Lipohypertrophy: A Systematic Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Skin manifestations in diabetes-what is new?Frontiers in medicine · 2025Review
- Access, awareness, and risk: drivers of unsafe sharps disposal and needle reuse in insulin-treated adults in China.Frontiers in public health · 2025Article
- Off the wall: incidental paraspinal and pelvic muscle pathology on abdominopelvic imaging.Abdominal radiology (New York) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipohypertrophy is a common skin complication associated with insulin-treated diabetes. The impact of lipohypertrophy as a contributing factor to suboptimal glycemic control, glucose variability, and hypoglycemia is often under-recognized by health care professionals. In a recent Webinar on April 26, 2023, Diabetes Technology Society asked international experts to provide updates on the latest knowledge related to lipohypertrophy for practicing clinicians and educators, researchers, and industries involved in insulin delivery. A recording of the Webinar is freely available on the Diabetes Technology Society Web site (https://www.diabetestechnology.org/).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.